GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (FRA:1S9) » Definitions » Valuation Rank

Seres Therapeutics (FRA:1S9) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is Seres Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Seres Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Seres Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Seres Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (FRA:1S9) » Definitions » Valuation Rank
Comparable Companies
ENTA SCPH RENB AEON INZY TCRX SELB IVVD GRTS DNTH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MCRB:USA
Address
101 Cambridgepark Drive, Cambridge, MA, USA, 02140
Website
https://www.serestherapeutics.com
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.